New vaccine aims to keep lung cancer drugs working longer
NCT ID NCT05950139
Summary
This early-stage study is testing a new vaccine designed to prevent or delay the cancer from becoming resistant to current targeted drugs in patients with advanced ALK-positive lung cancer. The vaccine aims to train the immune system to attack the cancer. Researchers will check if the vaccine is safe and if it triggers the desired immune response in about 12 patients who are already doing well on their standard ALK-targeted therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.